Moody Aldrich Partners LLC Sells 137,348 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Moody Aldrich Partners LLC trimmed its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 63.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,145 shares of the company’s stock after selling 137,348 shares during the period. Moody Aldrich Partners LLC owned about 0.09% of NewAmsterdam Pharma worth $2,034,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. HB Wealth Management LLC acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at $224,000. JPMorgan Chase & Co. increased its holdings in NewAmsterdam Pharma by 176.9% in the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after purchasing an additional 14,280 shares during the period. Barclays PLC increased its holdings in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Geode Capital Management LLC increased its holdings in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,399 shares during the period. Finally, M&T Bank Corp increased its holdings in NewAmsterdam Pharma by 54.1% in the third quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock valued at $454,000 after purchasing an additional 9,593 shares during the period. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the transaction, the insider now owns 11,812,033 shares of the company’s stock, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 446,730 shares of company stock worth $11,438,695 in the last three months. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $21.45 on Wednesday. The stock has a 50-day moving average of $23.46 and a 200-day moving average of $19.95. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NAMS. HC Wainwright reiterated a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, Scotiabank raised their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $41.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.